Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2005

01-05-2005 | Oral presentation

New agents for bone metastasis

Author: GN Hortobagyi

Published in: Breast Cancer Research | Special Issue 1/2005

Login to get access

Excerpt

Metastases to osseous structures represent the most common metastatic destination for human breast carcinoma. Conversely, breast cancer is one of the most common sources of bone metastases. Bone metastases produce multiple complications, including pain, pathological fractures, hypercalcemia, and spinal cord compression. Some of these complications are potentially catastrophic and all reduce the quality of life of patients with metastatic breast cancer. …
Metadata
Title
New agents for bone metastasis
Author
GN Hortobagyi
Publication date
01-05-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1234

Other articles of this Special Issue 1/2005

Breast Cancer Research 1/2005 Go to the issue

Poster presentation

A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

Oral presentation

Preoperative hormonal therapy: results and implications

Oral presentation

Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNPs) in metastatic breast cancer

Poster presentation

Clinical profile and management of bilateral breast cancer

Oral presentation

Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy (HDC)

Poster presentation

[ASCRIT] Antisense chemoradioimmunotherapy consisting of anti-POEM (Arg-Gly-Asp) scFv linked onto high-energy radioisotopes, vinorelbine-tartrate and 21-nucleotide double-stranded siRNA targeted to DNMT1 induce apoptosis in metastatic breast cancer (MBC) characterized by hypermethylated p53, p16, RASSF1A, RAR-b2, BRCA2, H1C1, ESRI1, CDH1, Trbeta1, GSTP1, CCND2 and overexpression of bcl-2, cdc25c, Raf-1 and α8β1 integrin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits